Reslizumab
Reslizumab is a humanized monoclonal antibody that specifically binds and neutralizes interleukin-5 (IL-5), the primary cytokine responsible for eosinophil proliferation, maturation, activation, and survival, thereby reducing blood and airway eosinophilia in allergic asthma. It is approved as add-on maintenance therapy for adults with severe eosinophilic asthma inadequately controlled on inhaled corticosteroids.
Aires thérapeutiques
Mécanisme d'action
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
Reslizumab is a humanized monoclonal antibody that specifically binds and neutralizes interleukin-5 (IL-5), the primary cytokine responsible for eosinophil proliferation, maturation, activation, and survival, thereby reducing blood and airway eosinophilia in allergic asthma. It is approved as add-on maintenance therapy for adults with severe eosinophilic asthma inadequately controlled on inhaled corticosteroids.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Reslizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107884. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="reslizumab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/reslizumab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/reslizumab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/reslizumab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="reslizumab"></drugfyi-drug>